EPS advantages of second-generation antipsychotics under scrutiny
A new report from the CATIE study has challenged claims that second-generation ‘atypical’ antipsychotics are associated with a lower risk of extra-pyramidal side effects (EPS) than first-generation medications....
Want to read complete article? Please Sign in or Register.